Stryker Corporation
SYK
$293.30
-2.06%
Stryker Corporation is a leading global medical technology company that designs, manufactures, and markets a diverse portfolio of medical equipment, instruments, consumable supplies, and implantable devices. It holds a dominant market position as one of the three largest competitors in reconstructive orthopedic implants and is the leader in operating room equipment. The current investor narrative is focused on the company's strategic expansion through acquisitions, such as the recent purchase of Amplitude Vascular Systems to bolster its peripheral vascular portfolio, and navigating the broader market pressures affecting the medical device sector, which have contributed to recent stock price volatility and a debate around its growth trajectory and valuation.…
SYK
Stryker Corporation
$293.30
Related headlines
SYK 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Stryker Corporation's 12-month outlook, with a consensus price target around $381.29 and implied upside of +30.0% versus the current price.
Average Target
$381.29
16 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
16
covering this stock
Price Range
$235 - $381
Analyst target range
A cohort of 16 analysts covers Stryker, with recent institutional ratings showing a mix of Buy, Outperform, and Hold actions, indicating a generally bullish to neutral consensus sentiment. The average revenue estimate for the upcoming period is $37.95 billion, with a high estimate of $38.39 billion and a low of $37.44 billion, reflecting a relatively tight range and strong conviction in the company's revenue trajectory. The target price range is not explicitly provided in the data, but the presence of multiple 'Buy' ratings from firms like Needham and BTIG in early 2026, alongside maintained 'Neutral' or 'Hold' ratings from others like UBS and Truist, signals a debate between optimism on execution and caution regarding near-term market headwinds or valuation.
SYK Technical Analysis
The stock is in a pronounced downtrend, with a 1-year price change of -20.21% and a 3-month decline of -21.26%. As of the latest close at $305.09, the price is trading at approximately 24% of its 52-week range ($281.00 to $404.87), positioning it much closer to its annual low, which suggests either a significant value opportunity or a stock experiencing fundamental deterioration. The short-term momentum shows a slight deceleration from the longer-term trend, with a 1-month decline of -3.19%, which is notably less severe than the 3-month and 1-year drops, hinting at a potential stabilization or consolidation phase after the steep sell-off. The stock's beta of 0.81 indicates it has been about 19% less volatile than the broader market (SPY), which gained 28.21% over the past year, highlighting its significant negative relative strength of -48.42% and its defensive nature during this specific decline. Key technical levels are clearly defined, with immediate support at the 52-week low of $281.00 and major resistance at the 52-week high of $404.87; a sustained breakdown below $281 would signal a continuation of the bearish trend, while a recovery above the recent highs near $387 from February would be necessary to suggest a trend reversal.
Beta
0.81
0.81x market volatility
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
$281-$405
Price range past year
Annual Return
-23.0%
Cumulative gain past year
| Period | SYK Return | S&P 500 |
|---|---|---|
| 1m | -0.5% | +5.4% |
| 3m | -23.2% | +10.9% |
| 6m | -19.5% | +11.0% |
| 1y | -23.0% | +28.1% |
| ytd | -15.8% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SYK Fundamental Analysis
Revenue growth remains robust, with Q4 2025 revenue of $7.17 billion representing an 11.42% year-over-year increase, and segment data shows a balanced contribution from MedSurg ($4.56B) and Orthopaedics ($4.96B). The multi-quarter trend shows consistent top-line expansion, with revenue growing from $5.24B in Q1 2024 to the recent $7.17B, supporting a stable growth investment case. Profitability is strong, with Q4 2025 net income of $849 million and a gross margin of 65.22%, which has expanded from 60.92% in Q1 2024, indicating effective cost management and pricing power. The net margin for the quarter was 11.84%, and the trailing twelve-month free cash flow of $4.28 billion underscores substantial cash generation. The balance sheet is healthy, with a current ratio of 1.89 and a debt-to-equity ratio of 0.66, reflecting manageable leverage. The company's return on equity of 14.48% and robust free cash flow yield, implied by the $4.28B FCF against a $134.3B market cap, demonstrate its ability to fund growth and return capital to shareholders without excessive reliance on external financing.
Quarterly Revenue
$7.2B
2025-12
Revenue YoY Growth
+0.11%
YoY Comparison
Gross Margin
+0.65%
Latest Quarter
Free Cash Flow
$4.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SYK Overvalued?
Given a positive net income of $849 million in the latest quarter, the primary valuation metric is the P/E ratio. The trailing P/E is 41.38x, while the forward P/E is significantly lower at 18.25x, indicating the market expects substantial earnings growth in the coming year. Compared to sector averages, Stryker's trailing P/E of 41.38x and Price/Sales ratio of 5.35x are at a premium to typical medical device peers, which often trade in the 20-30x P/E range, a premium justified by its market leadership, consistent growth, and high margins. Historically, the stock's own trailing P/E has ranged widely; the current 41.38x is below the peak of over 78x seen in early 2022 but above the low-20s seen in late 2023, suggesting valuation has compressed from optimistic highs but remains elevated relative to its own recent history, pricing in expectations of a growth recovery.
PE
41.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 23x~78x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.0x
Enterprise Value Multiple
